Targets › IL1RAP
5 programs from 5 companies in 8 trials: 3 Phase 1, 3 Phase 3, 1 Phase 4, 1 Phase 2; Oncology, Immunology, Respiratory; next expected readout Jun 2027.
Coreceptor for IL1RL2 in the IL-36 signaling system (By similarity). Coreceptor with IL1R1 in the IL-1 signaling system. (UniProt, Q9NPH3)
Open in Phaseline: the race on IL1RAP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| LEO Pharma | Spesolimab IL36 receptor antagonist | IL36R, IL1RAP | Phase 4 | Generalized Pustular Psoriasis; Pyoderma Gangrenosum | Sep 2027 |
| Roche | Astegolimab IL-33 receptor (ST2) inhibitor | IL1RAP, IL33R | Phase 3 | Chronic Obstructive Pulmonary Disease (COPD); Chronic Obstructive Pulmonary Disease | Jun 2027 |
| Shanghai Zhongshan Hospital | Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells IL1RAP-targeting CAR-T cell therapy | IL1RAP | Phase 1 | HCC | Dec 2027 |
| M.D. Anderson Cancer Center | Nadunolimab IL1RAP antibody | IL1RAP | Phase 1 | Myelodysplastic Syndrome(MDS) | Dec 2027 |
| Dan Feng | Nadunolimab Anti-IL-1RAP antibody | IL1RAP | Phase 1 | Metastatic Microsatellite Stable Colorectal Carcinoma | Dec 2028 |
Generalized Pustular Psoriasis (2) Myelodysplastic Syndrome(MDS) (1) Pyoderma Gangrenosum (1) Chronic Obstructive Pulmonary Disease (COPD) (1) Chronic Obstructive Pulmonary Disease (1) HCC (1) Metastatic Microsatellite Stable Colorectal Carcinoma (1)
mixed (2), antibody (2), other (1)
M.D. Anderson Cancer Center (1) LEO Pharma (1) Roche (1) Shanghai Zhongshan Hospital (1) Dan Feng (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.